MDMA

Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy

Retrieved on: 
Wednesday, November 8, 2023
Psilocybin, Science, Government, Post-traumatic stress disorder, Parliament, Anxiety, MDMA, Veterans Affairs Canada, MDD, Chronic pain, Public, DND, Treatment, Health Canada, Veteran, Government of Canada, Doctor of Philosophy, Research, National security, Equitable Access to Care and Health Act, Canadian Institutes of Health Research, PTSD, OUD, CIHR, Atypical depression, DSM-IV codes, AUD, Partnership, VAC, TUD, House, Safety, Nicotine, Veterans' affairs, TRD, Mental health, Senate, Pharmaceutical industry, Nursing

OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.

Key Points: 
  • OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.
  • While Canada is a leader in developing these innovative treatments, many barriers remain to patient access, and government must play an active role.
  • “This report echoes our calls for government funding into psychedelic-assisted therapy,” said PharmAla Biotech CEO and PsyCan Chair Nick Kadysh.
  • “Research on these subjects is constantly evolving and will continue to do so.

PharmAla Partners with Clariti Strategic Advisors™

Retrieved on: 
Wednesday, November 8, 2023
MDMA, OTC, Research, Armenia–EU Comprehensive and Enhanced Partnership Agreement, CSE, Partnership, MDXX, RSU, Pharmaceutical industry, Security (finance), Clarity Capital

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has signed an exclusive long-term agreement (the “Partnership Agreement”) with Clariti Strategic Advisors Inc. (“Clariti”) of Toronto, pursuant to which Clariti will provide strategic advisory and investment banking services to the Company.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has signed an exclusive long-term agreement (the “Partnership Agreement”) with Clariti Strategic Advisors Inc. (“Clariti”) of Toronto, pursuant to which Clariti will provide strategic advisory and investment banking services to the Company.
  • Clariti will provide advice to help PharmAla ensure that its long-term value to its stakeholders is at all times being considered and optimized.
  • Clariti, its subsidiaries and sub-agents will also advise as needed on: (i) the raising of capital through strategic investments at the corporate or subsidiary/joint venture level, (ii) significant/strategic investments by PharmAla, (iii) joint venture arrangements, (iv) mergers and acquisitions, and (v) the negotiation of strategic customer licensing or supply agreements.
  • We are proud to work with Clariti as our exclusive strategic advisor and investment banking partner moving forward,” said Nick Kadysh, CEO, PharmAla.

Psychedelics in Focus: Clinical Trials, Transformations and Regulations, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 8, 2023
Trial of the century, MDMA, Indian Radio Regulatory Service, Ibogaine, MAPS, Organization, Multidisciplinary Association for Psychedelic Studies, Senior, PTSD, Psilocybin, Science, Depression, Anxiety, Toxicity, Regulatory affairs, Pharmaceutical industry, Medical device

TORONTO, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder.

Key Points: 
  • Attendees will explore the specific aspects of psychedelics crucial for orchestrating clinical trials.
  • The featured speakers will discuss the regulatory landscape governing novel psychedelic clinical studies in Australia.
  • The speakers will also delve into the outlook for emerging psychedelic compounds and their potential impact on the future.
  • Discuss the important results observed in clinical trials, showcasing the potential for durable effects lasting over a year post-dosing.

SetSet, the Novel Psychedelic Card Game, to Premier at Wonderland Conference by Microdose

Retrieved on: 
Tuesday, November 7, 2023
Microdosing, MDMA, Integral Coach Factory, Burning Tree, Conference, Fear, Entrepreneurship, Pride, Friends, Eye, Infinite set, Anxiety, Patient, Beauty, Nightclub

Make your next journey extraordinary with SetSet

Key Points: 
  • Miami, Florida--(Newsfile Corp. - November 7, 2023) - SetSet the Psychedelic Integration Card Game, created by North American cannabis industry pioneers is premiering at Wonderland Conference by Microdose on November 9-11 in Booth #401.
  • SetSet is a deck of introspective, evocative "playing cards" inspired by the essential Set & Setting of any psychedelic journey.
  • Together the teams focus on building a unique market and develop a unique experience through play.
  • By providing structure in the form of a card game, SetSet can also reduce anxiety and, therefore, the potential "bad trip" experiences.

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Retrieved on: 
Tuesday, November 7, 2023
Psilocybin, ASX, JV, Sale, MDMA, OTC, Research, CSE, Joint venture, Clinical trial, API, MDXX, GMP, Authorization, Patient, Pharmaceutical industry

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian Joint Venture with Vitura Health Limited (ASX: VIT).

Key Points: 
  • VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian Joint Venture with Vitura Health Limited (ASX: VIT).
  • This shipment marks the first time that any molecules recently re-scheduled under the Authorized Prescriber Scheme were brought into Australia explicitly for use under that scheme, rather than for clinical trial purposes.
  • The shipment, completed in several parts, includes both psilocybin and MDMA, and contains a both API and finished drug product capsules.
  • “As PharmAla’s JV partner in Cortexa, we at Vitura Health are proud to continue to lead the industry in the provision of both of GMP grade Psilocybin and MDMA, which will be used in treating patients as soon as possible.

Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer

Retrieved on: 
Tuesday, November 7, 2023
MDMA, CSO, Analytic, FRA, History, University of Victoria, Y Touring Theatre Company, Research and development, Doctor of Philosophy, Catalysis, Research, CSE, Interview, University, GMP, Communication, Chase, Pharmaceutical industry, Management

Chase as the Company’s Chief Science Officer (“CSO”).

Key Points: 
  • Chase as the Company’s Chief Science Officer (“CSO”).
  • Dr. Chase is a distinguished Research & Development (“R&D”) chemist and seasoned business professional with an impressive academic and industrial track record spanning over 25 years.
  • Optimi Health CEO Bill Ciprick conveyed his excitement regarding Dr. Chase's addition to the team, remarking, “Dr.
  • Optimi Health warmly welcomes both Dr. Chase and Ms. Ranger to the Optimi team and anticipates an era of remarkable scientific progress under their guidance.

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Retrieved on: 
Tuesday, November 7, 2023
WHO, FDA, MDMA, Radioisotope Production Facility, Psilocybin, Mycology, Prohibition of drugs, EMA, Psilocybe, Safety, License, General counsel, Pharmaceutical industry

The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.

Key Points: 
  • The Company is current growing weekly with authorization to store up to 250,000 kg of dried psilocybin-containing mushrooms on-site, or the equivalent of 1,250 kg of psilocybin.
  • PurMinds™ is currently able to supply its psilocybin mushrooms in dried whole mushroom form, or milled and encapsulated, with potency analyses reaching average total tryptamine levels of up to 1.03%.
  • To support patient safety and practitioner confidence, each batch is also tested for impurities.
  • "The specialized expertise that our scientists and cultivation team possess, coupled with the Company's strong focus on safety, efficacy and profitability, has ideally positioned PurMinds to be at the forefront of legal natural psilocybin mushroom supply."

Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing

Retrieved on: 
Thursday, November 2, 2023
MDMA, CAD, FRA, FOR, Health Canada, Creditor, DFA, GSA, Warrant, CSE, Loan, GMP, Security (finance)

Upon maturity of the Loan, all outstanding principal shall be payable on April 30, 2025.

Key Points: 
  • Upon maturity of the Loan, all outstanding principal shall be payable on April 30, 2025.
  • The Company may repay the Loan at any time on notice to the Lender, subject to a prepayment fee.
  • The Warrants are exercisable for three (3) years from the date of issuance, at $0.50.
  • FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Cordis Announces Scott Drake as Chief Executive Officer

Retrieved on: 
Monday, November 6, 2023
Paragon, FNA, MDMA, EQT, Medical device, Executive, ATRC, Zayo Group, Patient, MIAMI, H&F, Management, Cordis

MIAMI LAKES, Fla., Nov. 6, 2023 /PRNewswire/ -- Cordis announced that its Board of Directors has appointed Scott Drake as Chief Executive Officer (CEO) effective immediately.

Key Points: 
  • MIAMI LAKES, Fla., Nov. 6, 2023 /PRNewswire/ -- Cordis announced that its Board of Directors has appointed Scott Drake as Chief Executive Officer (CEO) effective immediately.
  • Mr. Drake most recently held the position of Executive Chairman of the Cordis Board of Directors.
  • "Scott Drake has been on the Cordis Board of Directors since we acquired Cordis in 2021," said Hunter Philbrick, H&F partner and Cordis board member.
  • Scott believes in Cordis' ability to transform the medical industry, and with him as CEO, Cordis will achieve its vision of pioneering breakthrough cardiovascular technologies."

Oakland activists file statewide ballot initiative seeking safe and legal access to psychedelics for medical and therapeutic uses

Retrieved on: 
Saturday, October 28, 2023
Alternative Medicine, Public Policy, Government, Cannabis, State, Local, Health, Advocacy Group Opinion, Natural Resources, Psilocybin, Post-traumatic stress disorder, Mescaline, Sale, MDMA, Hodges, Johns Hopkins, Quality control, PTSD, Traumatic brain injury, Suicide, DMT, Psychedelic drug, Language, Depression, Anxiety, Tic disorder, Addiction, Mental health, Senate, Nursing

Dave Hodges, proponent of safe access to psychedelics for medical, therapeutic and spiritual use, today submitted the Psychedelic Wellness & Healing Initiative to the California Attorney General’s office for the 2024 ballot.

Key Points: 
  • Dave Hodges, proponent of safe access to psychedelics for medical, therapeutic and spiritual use, today submitted the Psychedelic Wellness & Healing Initiative to the California Attorney General’s office for the 2024 ballot.
  • If it wins passage, the initiative will allow for the sale, possession and use of psychedelics including Psilocybin, MDMA, DMT, and Mescaline for medical and therapeutic purposes.
  • Hodges, founder of the Oakland-based Church of Ambrosia , said the initiative will need 546,651 valid signatures to qualify for the 2024 ballot.
  • The initiative also would create a statewide framework for regulating possession, use, cultivation and production of substances for medical and therapeutic use.